Neutralising antibodies against ricin toxin.
The Centers for Disease Control and Prevention have listed the potential bioweapon ricin as a Category B Agent. Ricin is a so-called A/B toxin produced by plants and is one of the deadliest molecules known. It is easy to prepare and no curative treatment is available. An immunotherapeutic approach c...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2011-01-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC3102095?pdf=render |
| _version_ | 1818587556368875520 |
|---|---|
| author | Julie Prigent Laetitia Panigai Patricia Lamourette Didier Sauvaire Karine Devilliers Marc Plaisance Hervé Volland Christophe Créminon Stéphanie Simon |
| author_facet | Julie Prigent Laetitia Panigai Patricia Lamourette Didier Sauvaire Karine Devilliers Marc Plaisance Hervé Volland Christophe Créminon Stéphanie Simon |
| author_sort | Julie Prigent |
| collection | DOAJ |
| description | The Centers for Disease Control and Prevention have listed the potential bioweapon ricin as a Category B Agent. Ricin is a so-called A/B toxin produced by plants and is one of the deadliest molecules known. It is easy to prepare and no curative treatment is available. An immunotherapeutic approach could be of interest to attenuate or neutralise the effects of the toxin. We sought to characterise neutralising monoclonal antibodies against ricin and to develop an effective therapy. For this purpose, mouse monoclonal antibodies (mAbs) were produced against the two chains of ricin toxin (RTA and RTB). Seven mAbs were selected for their capacity to neutralise the cytotoxic effects of ricin in vitro. Three of these, two anti-RTB (RB34 and RB37) and one anti-RTA (RA36), when used in combination improved neutralising capacity in vitro with an IC(50) of 31 ng/ml. Passive administration of association of these three mixed mAbs (4.7 µg) protected mice from intranasal challenges with ricin (5 LD(50)). Among those three antibodies, anti-RTB antibodies protected mice more efficiently than the anti-RTA antibody. The combination of the three antibodies protected mice up to 7.5 hours after ricin challenge. The strong in vivo neutralising capacity of this three mAbs combination makes it potentially useful for immunotherapeutic purposes in the case of ricin poisoning or possibly for prevention. |
| first_indexed | 2024-12-16T09:10:44Z |
| format | Article |
| id | doaj.art-9d60a5ce758946afa02ebd223863ba6a |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-16T09:10:44Z |
| publishDate | 2011-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-9d60a5ce758946afa02ebd223863ba6a2022-12-21T22:37:00ZengPublic Library of Science (PLoS)PLoS ONE1932-62032011-01-0165e2016610.1371/journal.pone.0020166Neutralising antibodies against ricin toxin.Julie PrigentLaetitia PanigaiPatricia LamouretteDidier SauvaireKarine DevilliersMarc PlaisanceHervé VollandChristophe CréminonStéphanie SimonThe Centers for Disease Control and Prevention have listed the potential bioweapon ricin as a Category B Agent. Ricin is a so-called A/B toxin produced by plants and is one of the deadliest molecules known. It is easy to prepare and no curative treatment is available. An immunotherapeutic approach could be of interest to attenuate or neutralise the effects of the toxin. We sought to characterise neutralising monoclonal antibodies against ricin and to develop an effective therapy. For this purpose, mouse monoclonal antibodies (mAbs) were produced against the two chains of ricin toxin (RTA and RTB). Seven mAbs were selected for their capacity to neutralise the cytotoxic effects of ricin in vitro. Three of these, two anti-RTB (RB34 and RB37) and one anti-RTA (RA36), when used in combination improved neutralising capacity in vitro with an IC(50) of 31 ng/ml. Passive administration of association of these three mixed mAbs (4.7 µg) protected mice from intranasal challenges with ricin (5 LD(50)). Among those three antibodies, anti-RTB antibodies protected mice more efficiently than the anti-RTA antibody. The combination of the three antibodies protected mice up to 7.5 hours after ricin challenge. The strong in vivo neutralising capacity of this three mAbs combination makes it potentially useful for immunotherapeutic purposes in the case of ricin poisoning or possibly for prevention.http://europepmc.org/articles/PMC3102095?pdf=render |
| spellingShingle | Julie Prigent Laetitia Panigai Patricia Lamourette Didier Sauvaire Karine Devilliers Marc Plaisance Hervé Volland Christophe Créminon Stéphanie Simon Neutralising antibodies against ricin toxin. PLoS ONE |
| title | Neutralising antibodies against ricin toxin. |
| title_full | Neutralising antibodies against ricin toxin. |
| title_fullStr | Neutralising antibodies against ricin toxin. |
| title_full_unstemmed | Neutralising antibodies against ricin toxin. |
| title_short | Neutralising antibodies against ricin toxin. |
| title_sort | neutralising antibodies against ricin toxin |
| url | http://europepmc.org/articles/PMC3102095?pdf=render |
| work_keys_str_mv | AT julieprigent neutralisingantibodiesagainstricintoxin AT laetitiapanigai neutralisingantibodiesagainstricintoxin AT patricialamourette neutralisingantibodiesagainstricintoxin AT didiersauvaire neutralisingantibodiesagainstricintoxin AT karinedevilliers neutralisingantibodiesagainstricintoxin AT marcplaisance neutralisingantibodiesagainstricintoxin AT hervevolland neutralisingantibodiesagainstricintoxin AT christophecreminon neutralisingantibodiesagainstricintoxin AT stephaniesimon neutralisingantibodiesagainstricintoxin |